Equities Analysts Issue Forecasts for APTO FY2024 Earnings

Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) – Analysts at HC Wainwright issued their FY2024 earnings per share estimates for Aptose Biosciences in a note issued to investors on Wednesday, November 20th. HC Wainwright analyst J. Pantginis forecasts that the biotechnology company will post earnings per share of ($1.79) for the year. HC Wainwright currently has a “Buy” rating and a $2.00 price target on the stock. The consensus estimate for Aptose Biosciences’ current full-year earnings is ($1.79) per share. HC Wainwright also issued estimates for Aptose Biosciences’ Q4 2024 earnings at ($0.35) EPS.

Separately, StockNews.com began coverage on shares of Aptose Biosciences in a research note on Thursday, November 21st. They set a “hold” rating on the stock.

Aptose Biosciences Stock Performance

Shares of Aptose Biosciences stock opened at $0.18 on Monday. Aptose Biosciences has a one year low of $0.13 and a one year high of $2.91. The company has a market cap of $3.34 million, a P/E ratio of -0.06 and a beta of 1.26. The firm has a fifty day moving average of $0.38 and a two-hundred day moving average of $0.60.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Aptose Biosciences stock. Sigma Planning Corp lifted its stake in shares of Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) by 71.3% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 401,750 shares of the biotechnology company’s stock after purchasing an additional 167,282 shares during the quarter. Sigma Planning Corp owned about 2.22% of Aptose Biosciences worth $165,000 at the end of the most recent quarter. 26.62% of the stock is owned by institutional investors and hedge funds.

Aptose Biosciences Company Profile

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.